Bristol-Myers Squibb

BMS Kicks Off 2021 with $70 Million Collab for Next-Gen T Cell Cancer Therapies
BMS Kicks Off 2021 with $70 Million Collab for Next-Gen T Cell Cancer Therapies
BioSpace
Bristol-Myers Squibb
ArsenalBio
solid tumors
t-cell therapies
Flag link:
Astrazeneca shows megamergers were still possible in 2020
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
Flag link:
BMS/Celgene merger payout evaporates as CVR deadline passes
BMS/Celgene merger payout evaporates as CVR deadline passes
Pharmaforum
Celgene
Bristol-Myers Squibb
FDA
CVRs
Flag link:
Corporate and regulatory developments over the holidays
Corporate and regulatory developments over the holidays
EP Vantage
AstraZeneca
Bristol-Myers Squibb
Celltrion
Cullinan Oncology
JNJ
Myovant Sciences
Osmotica Pharmaceuticals
Pfizer
Y-mAbs Therapeutics
United Therapeutics
Zai Lab
Flag link:
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Fierce Pharma
Merck
Bristol-Myers Squibb
AstraZeneca
Roche
Keytruda
Opdivo
Imfinzi
Tecentriq
China
PD-1 inhibitors
Flag link:
Bristol Myers Squibb’s Opdivo Brain Tumor Trial Fails Mid-Trial Assessment
Bristol Myers Squibb’s Opdivo Brain Tumor Trial Fails Mid-Trial Assessment
BioSpace
Bristol-Myers Squibb
Opdivo
clinical trials
brain tumors
Flag link:
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA
Pharmaforum
JNJ
Janssen
Multiple Myeloma
CAR-T
cilta-cel
FDA
Bristol-Myers Squibb
ide-cel
Flag link:
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
Endpoints
Bristol-Myers Squibb
liso-cel
drug manufacturing
Celgene
CVRs
Flag link:
$200M investment to advance clinical programs for Ambrx
$200M investment to advance clinical programs for Ambrx
MedCity News
Ambrx
oncology
Astellas
BeiGene
Bristol-Myers Squibb
Flag link:
Bristol Myers Squibb Closes $13.1 Billion Acquisition of MyoKardia
Bristol Myers Squibb Closes $13.1 Billion Acquisition of MyoKardia
Motley Fool
Bristol-Myers Squibb
MyoKardia
M&A
Flag link:
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
Endpoints
Bristol-Myers Squibb
CVRs
Celgene
M&A
Flag link:
A cancer vaccine that might work? Moderna posts 'promising' early snapshot for Merck-partnered program and raids Bristol Myers for a new cancer R&D chief
A cancer vaccine that might work? Moderna posts 'promising' early snapshot for Merck-partnered program and raids Bristol Myers for a new cancer R&D chief
Endpoints
Moderna Therapeutics
MRNA
vaccines
cancer vaccines
mRNA-4157
Bristol-Myers Squibb
Flag link:
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?
Pharmaforum
Bristol-Myers Squibb
liso-cel
CVRs
Flag link:
How Bristol Myers Squibb Beat Wall Street Estimates in Q3
How Bristol Myers Squibb Beat Wall Street Estimates in Q3
Motley Fool
Bristol-Myers Squibb
earnings
Flag link:
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Fierce Pharma
Celgene
Bristol-Myers Squibb
Zeposia
Reblozyl
Onureg
Flag link:
Why AstraZeneca, Bristol Myers Squibb, and Eli Lilly Stocks Jumped Today
Why AstraZeneca, Bristol Myers Squibb, and Eli Lilly Stocks Jumped Today
Motley Fool
pharma stocks
2020 Presidential election
Eli Lilly
Bristol-Myers Squibb
AstraZeneca
Flag link:
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
Motley Fool
Bristol-Myers Squibb
M&A
Celgene
MyoKardia
Flag link:
Bristol Myers' psoriasis drug beats Amgen rival in phase 3
Bristol Myers' psoriasis drug beats Amgen rival in phase 3
Fierce Biotech
Bristol-Myers Squibb
deucravacitinib
Amgen
Otezla
clinial trials
plaque psoriasis
Flag link:
Jounce shares crash after it abandons immunotherapy combination trial
Jounce shares crash after it abandons immunotherapy combination trial
Pharmaforum
Jounce Therapeutics
non-small cell lung cancer
Bristol-Myers Squibb
Yervoy
Flag link:
Eliquis partners BMS and Pfizer join the pharma crowd urging doctor visits during COVID-19
Eliquis partners BMS and Pfizer join the pharma crowd urging doctor visits during COVID-19
Fierce Pharma
Pfizer
Bristol-Myers Squibb
Eliquis
DTC advertising
pandemic
COVID-19
Flag link:

Pages